Catherine Owen Adams Takes the Helm as CEO of Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is in the spotlight with the announcement that Catherine Owen Adams has been appointed as the new Chief Executive Officer (CEO), taking over from Steve Davis. This shift in leadership is a pivotal chapter for the company as it continues its journey in the pharmaceutical industry.
Embracing a New Chapter
Stephen Biggar, M.D., Ph.D., Chair of the Board, expressed his excitement regarding Adams's appointment, saying, "We are thrilled to welcome Catherine Owen Adams as the new CEO of Acadia. Catherine is a proven global leader with an impressive record in the pharmaceutical sector." As Acadia aims to strengthen its presence in the market, her strategic vision and dedication to improving patient outcomes are invaluable, especially as the company approaches $1 billion in sales.
A Bright Horizon for Acadia
Biggar highlighted the company’s promising growth potential under Adams’s leadership, especially in the areas of central nervous system disorders and rare diseases. Her experience and expertise are expected to guide Acadia into its next phase of growth and innovation.
Appreciation for Steve Davis
As this transition takes place, the board conveyed their heartfelt gratitude for Steve Davis's leadership. During his tenure, Acadia successfully launched groundbreaking therapies such as NUPLAZID and DAYBUE, which have made a significant difference in treatment options. His contributions have firmly established Acadia’s reputation in the biopharmaceutical field.
Adams's Vision and Dedication
Adams expressed her enthusiasm about joining Acadia during this critical and dynamic period for the organization. She stated, "I am thrilled to join Acadia at such a pivotal and dynamic time for the company." Adams is committed to driving growth in commercial franchises, while also fostering innovative partnerships and developing therapies that resonate with Acadia's mission.
Adams's Wealth of Experience
Before her new role at Acadia, Adams was the Senior Vice President and General Manager at Bristol Myers Squibb (BMS), where she managed a commercial portfolio valued at $20 billion. Her extensive leadership history includes key positions in significant markets across Europe, Japan, and Canada. With over 25 years at Johnson & Johnson, Adams has built a comprehensive understanding of various facets of the pharmaceutical industry.
A Commitment to Advancing Healthcare
Adams began her career in R&D at AstraZeneca and brings a rich background to her role. She holds a BSc in Pharmacy from the University of Manchester and is a member of the Royal Pharmaceutical Society. Her diverse expertise aligns well with Acadia's mission to enhance patient lives through innovative neuroscience solutions.
About Acadia Pharmaceuticals
Acadia Pharmaceuticals has been at the forefront of neuroscience advancements for three decades, being the first to gain FDA approval for a medication addressing hallucinations and delusions associated with Parkinson’s disease psychosis, as well as treatments for Rett syndrome. The company is currently focused on clinical programs that target Alzheimer’s disease psychosis and Prader-Willi syndrome, among others. Acadia's dedication to innovation positions it as a leader in tackling complex neuropsychiatric challenges.
Frequently Asked Questions
1. Who is the newly appointed CEO of Acadia Pharmaceuticals?
Catherine Owen Adams has taken over from Steve Davis as the new CEO of Acadia Pharmaceuticals.
2. Why is Catherine Owen Adams's appointment significant?
Her extensive experience and strategic outlook are expected to propel Acadia in addressing central nervous system disorders and broaden their commercial reach.
3. What notable achievements has Acadia Pharmaceuticals made under Steve Davis?
Davis was instrumental in securing approvals and launching critical medications like NUPLAZID and DAYBUE, which significantly improved patient care.
4. What industries has Catherine Owen Adams worked in prior to Acadia?
Adams boasts a wealth of experience in the pharmaceutical sector, having held leadership roles at companies such as Bristol Myers Squibb and Johnson & Johnson.
5. What is Acadia's future focus?
Acadia aims to drive innovation in neuroscience and provide therapies that address complex disorders, ultimately enhancing the quality of life for patients.
